Anti-TNFα blockers have rapidly become a standard treatment for rheumatoid (RA) and psoriatic arthritis (PsA) because of their acceptable safety profile and efficacy. Clinical and radiological remission may now be a realistic outcome and constitutes the best achievable state. However, clinical practice guidelines and consensus statements on the criteria of introduction, duration and cessation of treatment are under constant revision. Evidence supports that the early use of biologic DMARDs would produce rapid and sustained suppression of inflammatory disease and preserve function and joint erosions. Proof of this concept, anti-TNFα agents would be effective in maintaining response after cessation of treatment. Conversely, when therapy with anti-TNFα is withdrawn, the disease rapidly returns. Remission may be defined as minimal or no clinically detectable disease activity in the presence of continuing drug treatment and a rapid control of disease activity may prevent irreversible damage and disability. The use of US-PD and MRI in the early detection of disease recurrence could become necessary to prevent the relapse and direct the clinician's choice concerning a re-treatment regimen. The use of biological treatment can be for a limited period, at a time when it has the greatest opportunity to make the difference. © 2011 Elsevier B.V.

Chimenti, M.s., Graceffa, D., Perricone, R. (2011). Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?. AUTOIMMUNITY REVIEWS, 10(10), 636-640 [10.1016/j.autrev.2011.04.015].

Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?

CHIMENTI, MARIA SOLE;GRACEFFA, DARIO;PERRICONE, ROBERTO
2011

Abstract

Anti-TNFα blockers have rapidly become a standard treatment for rheumatoid (RA) and psoriatic arthritis (PsA) because of their acceptable safety profile and efficacy. Clinical and radiological remission may now be a realistic outcome and constitutes the best achievable state. However, clinical practice guidelines and consensus statements on the criteria of introduction, duration and cessation of treatment are under constant revision. Evidence supports that the early use of biologic DMARDs would produce rapid and sustained suppression of inflammatory disease and preserve function and joint erosions. Proof of this concept, anti-TNFα agents would be effective in maintaining response after cessation of treatment. Conversely, when therapy with anti-TNFα is withdrawn, the disease rapidly returns. Remission may be defined as minimal or no clinically detectable disease activity in the presence of continuing drug treatment and a rapid control of disease activity may prevent irreversible damage and disability. The use of US-PD and MRI in the early detection of disease recurrence could become necessary to prevent the relapse and direct the clinician's choice concerning a re-treatment regimen. The use of biological treatment can be for a limited period, at a time when it has the greatest opportunity to make the difference. © 2011 Elsevier B.V.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/16 - Reumatologia
English
Con Impact Factor ISI
Anti-TNF discontinuation; Disease relapse; Disease remission; Psoriatic arthritis; Rheumatoid arthritis; Animals; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Practice Guidelines as Topic; Remission Induction; Secondary Prevention; Tumor Necrosis Factor-alpha; Withholding Treatment; Immunology; Immunology and Allergy
Chimenti, M.s., Graceffa, D., Perricone, R. (2011). Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission?. AUTOIMMUNITY REVIEWS, 10(10), 636-640 [10.1016/j.autrev.2011.04.015].
Chimenti, Ms; Graceffa, D; Perricone, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Anti-TNF! discontinuation in rheumatoid and psoriatic.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 167.5 kB
Formato Adobe PDF
167.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119641
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact